Use of Imaging and Diagnostic Procedures After Low-Dose CT Screening for Lung Cancer

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Clinical trials have demonstrated a mortality benefit from lung cancer screening by low-dose CT (LDCT) in current or past tobacco smokers who meet criteria. Potential harms of screening mostly relate to downstream evaluation of abnormal screens. Few data exist on the rates outside of clinical trials of imaging and diagnostic procedures following screening LDCT. We describe rates in the community setting of follow-up imaging and diagnostic procedures after screening LDCT. Methods: We used Clinformatics Data Mart national database to identify enrollees age 55 to 80 year who underwent screening LDCT from January 1, 2016, to December 31, 2016. We assessed rates of follow-up imaging (diagnostic chest CT scan, MRI, and PET) and follow-up procedures (bronchoscopy, percutaneous biopsy, thoracotomy, mediastinoscopy, and thoracoscopy) in the 12 months following LDCT for lung cancer screening. We also assessed these rates in an age-, sex-, and number of comorbidities-matched population that did not undergo LDCT to estimate rates unrelated to the screening LDCT. We then reported the adjusted rate of follow-up testing as the observed rate in the screening LDCT population minus the rate in the non-LDCT population. Results: Among 11,520 enrollees aged 55 to 80 years who underwent LDCT in 2016, the adjusted rates of follow up 12 months after LDCT examinations were low (17.7% for imaging and 3.1% for procedures). Among procedures, the adjusted rates were 2.0% for bronchoscopy, 1.3% for percutaneous biopsy, 0.9% for thoracoscopy, 0.2% for mediastinoscopy, and 0.4% for thoracotomy. Adjusted rates of follow-up procedures were higher in enrollees undergoing an initial screening LDCT (3.3%) than in those after a second screening examination (2.2%). Conclusions: In general, imaging and rates of procedures after screening LDCT was low in this commercially insured population.

Original languageEnglish (US)
JournalChest
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Diagnostic Imaging
Lung Neoplasms
Mediastinoscopy
Thoracoscopy
Bronchoscopy
Thoracotomy
Early Detection of Cancer
Population
Clinical Trials
Biopsy
Tobacco
Comorbidity
Thorax
Databases
Mortality

Keywords

  • chest imaging
  • computed tomography
  • follow up
  • health-care utilization
  • imaging
  • LDCT
  • lung cancer screening
  • NLST
  • procedures

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

@article{df3b71b12ae745dab305e82a55cab84d,
title = "Use of Imaging and Diagnostic Procedures After Low-Dose CT Screening for Lung Cancer",
abstract = "Background: Clinical trials have demonstrated a mortality benefit from lung cancer screening by low-dose CT (LDCT) in current or past tobacco smokers who meet criteria. Potential harms of screening mostly relate to downstream evaluation of abnormal screens. Few data exist on the rates outside of clinical trials of imaging and diagnostic procedures following screening LDCT. We describe rates in the community setting of follow-up imaging and diagnostic procedures after screening LDCT. Methods: We used Clinformatics Data Mart national database to identify enrollees age 55 to 80 year who underwent screening LDCT from January 1, 2016, to December 31, 2016. We assessed rates of follow-up imaging (diagnostic chest CT scan, MRI, and PET) and follow-up procedures (bronchoscopy, percutaneous biopsy, thoracotomy, mediastinoscopy, and thoracoscopy) in the 12 months following LDCT for lung cancer screening. We also assessed these rates in an age-, sex-, and number of comorbidities-matched population that did not undergo LDCT to estimate rates unrelated to the screening LDCT. We then reported the adjusted rate of follow-up testing as the observed rate in the screening LDCT population minus the rate in the non-LDCT population. Results: Among 11,520 enrollees aged 55 to 80 years who underwent LDCT in 2016, the adjusted rates of follow up 12 months after LDCT examinations were low (17.7{\%} for imaging and 3.1{\%} for procedures). Among procedures, the adjusted rates were 2.0{\%} for bronchoscopy, 1.3{\%} for percutaneous biopsy, 0.9{\%} for thoracoscopy, 0.2{\%} for mediastinoscopy, and 0.4{\%} for thoracotomy. Adjusted rates of follow-up procedures were higher in enrollees undergoing an initial screening LDCT (3.3{\%}) than in those after a second screening examination (2.2{\%}). Conclusions: In general, imaging and rates of procedures after screening LDCT was low in this commercially insured population.",
keywords = "chest imaging, computed tomography, follow up, health-care utilization, imaging, LDCT, lung cancer screening, NLST, procedures",
author = "Nishi, {Shawn P.E.} and Jie Zhou and Ikenna Okereke and Kuo, {Yong Fang} and James Goodwin",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.chest.2019.08.2187",
language = "English (US)",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",

}

TY - JOUR

T1 - Use of Imaging and Diagnostic Procedures After Low-Dose CT Screening for Lung Cancer

AU - Nishi, Shawn P.E.

AU - Zhou, Jie

AU - Okereke, Ikenna

AU - Kuo, Yong Fang

AU - Goodwin, James

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Clinical trials have demonstrated a mortality benefit from lung cancer screening by low-dose CT (LDCT) in current or past tobacco smokers who meet criteria. Potential harms of screening mostly relate to downstream evaluation of abnormal screens. Few data exist on the rates outside of clinical trials of imaging and diagnostic procedures following screening LDCT. We describe rates in the community setting of follow-up imaging and diagnostic procedures after screening LDCT. Methods: We used Clinformatics Data Mart national database to identify enrollees age 55 to 80 year who underwent screening LDCT from January 1, 2016, to December 31, 2016. We assessed rates of follow-up imaging (diagnostic chest CT scan, MRI, and PET) and follow-up procedures (bronchoscopy, percutaneous biopsy, thoracotomy, mediastinoscopy, and thoracoscopy) in the 12 months following LDCT for lung cancer screening. We also assessed these rates in an age-, sex-, and number of comorbidities-matched population that did not undergo LDCT to estimate rates unrelated to the screening LDCT. We then reported the adjusted rate of follow-up testing as the observed rate in the screening LDCT population minus the rate in the non-LDCT population. Results: Among 11,520 enrollees aged 55 to 80 years who underwent LDCT in 2016, the adjusted rates of follow up 12 months after LDCT examinations were low (17.7% for imaging and 3.1% for procedures). Among procedures, the adjusted rates were 2.0% for bronchoscopy, 1.3% for percutaneous biopsy, 0.9% for thoracoscopy, 0.2% for mediastinoscopy, and 0.4% for thoracotomy. Adjusted rates of follow-up procedures were higher in enrollees undergoing an initial screening LDCT (3.3%) than in those after a second screening examination (2.2%). Conclusions: In general, imaging and rates of procedures after screening LDCT was low in this commercially insured population.

AB - Background: Clinical trials have demonstrated a mortality benefit from lung cancer screening by low-dose CT (LDCT) in current or past tobacco smokers who meet criteria. Potential harms of screening mostly relate to downstream evaluation of abnormal screens. Few data exist on the rates outside of clinical trials of imaging and diagnostic procedures following screening LDCT. We describe rates in the community setting of follow-up imaging and diagnostic procedures after screening LDCT. Methods: We used Clinformatics Data Mart national database to identify enrollees age 55 to 80 year who underwent screening LDCT from January 1, 2016, to December 31, 2016. We assessed rates of follow-up imaging (diagnostic chest CT scan, MRI, and PET) and follow-up procedures (bronchoscopy, percutaneous biopsy, thoracotomy, mediastinoscopy, and thoracoscopy) in the 12 months following LDCT for lung cancer screening. We also assessed these rates in an age-, sex-, and number of comorbidities-matched population that did not undergo LDCT to estimate rates unrelated to the screening LDCT. We then reported the adjusted rate of follow-up testing as the observed rate in the screening LDCT population minus the rate in the non-LDCT population. Results: Among 11,520 enrollees aged 55 to 80 years who underwent LDCT in 2016, the adjusted rates of follow up 12 months after LDCT examinations were low (17.7% for imaging and 3.1% for procedures). Among procedures, the adjusted rates were 2.0% for bronchoscopy, 1.3% for percutaneous biopsy, 0.9% for thoracoscopy, 0.2% for mediastinoscopy, and 0.4% for thoracotomy. Adjusted rates of follow-up procedures were higher in enrollees undergoing an initial screening LDCT (3.3%) than in those after a second screening examination (2.2%). Conclusions: In general, imaging and rates of procedures after screening LDCT was low in this commercially insured population.

KW - chest imaging

KW - computed tomography

KW - follow up

KW - health-care utilization

KW - imaging

KW - LDCT

KW - lung cancer screening

KW - NLST

KW - procedures

UR - http://www.scopus.com/inward/record.url?scp=85075503450&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075503450&partnerID=8YFLogxK

U2 - 10.1016/j.chest.2019.08.2187

DO - 10.1016/j.chest.2019.08.2187

M3 - Article

C2 - 31521671

AN - SCOPUS:85075503450

JO - Chest

JF - Chest

SN - 0012-3692

ER -